DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Innocenti, F.
Right arrow Articles by Ratain, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Innocenti, F.
Right arrow Articles by Ratain, M. J.

Vol. 29, Issue 5, 686-692, May 2001

Epirubicin Glucuronidation Is Catalyzed by Human UDP-Glucuronosyltransferase 2B7

Federico Innocenti, Lalitha Iyer, Jacqueline Ramírez, Mitchell D. Green, and Mark J. Ratain

The University of Chicago, Department of Medicine (F.I., L.I., J.R., M.J.R.), Committee on Clinical Pharmacology (L.I., M.J.R.), Cancer Research Center (M.J.R.), Chicago, Illinois; and The University of Iowa, Department of Pharmacology (M.D.G.), Iowa City, Iowa

Epirubicin is one of the most active agents for breast cancer. The formation of epirubicin glucuronide by liver UDP-glucuronosyltransferase (UGT) is its main inactivating pathway. This study aimed to investigate epirubicin glucuronidation in human liver microsomes, to identify the specific UGT isoform for this reaction, and to correlate epirubicin glucuronidation with other UGT substrates. Microsomes from human livers were used. UGTs specifically expressed in cellular systems, as well as two UGT2B7 variants, were screened for epirubicin glucuronidation. Epirubicin, morphine, and SN-38 glucuronides were measured by high-pressure liquid chromatography. The mean ± S.D. formation rate of epirubicin glucuronide in human liver microsomes (n = 47) was 138 ± 37 pmol/min/mg (coefficient of variation, 24%). This phenotype was normally distributed. We screened commercially available UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 for epirubicin glucuronidation. Only UGT2B7 converted epirubicin to its glucuronide. No differences in epirubicin glucuronidation were found in HK293 cells expressing the two UGT2B7 variants at position 268. Catalytic efficiency (Vmax/Km) of epirubicin glucuronidation was 1.4 µl/min/mg, a value higher than that observed for morphine, a substrate of UGT2B7. Formation of epirubicin glucuronide was significantly related to that of morphine-3-glucuronide (r = 0.76, p < 0.001) and morphine-6-glucuronide (r = 0.73, p < 0.001). No correlation was found with SN-38, a substrate of UGT1A1 (r = 0.04). UGT2B7 is the major human UGT catalyzing epirubicin glucuronidation, and UGT2B7 is the candidate gene for this phenotype. The reported tyrosine to histidine polymorphism in UGT2B7 does not alter the formation rate of epirubicin glucuronide, and undiscovered genetic polymorphisms in UGT2B7 might change the metabolic fate of this important anticancer agent.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
K. Bowalgaha, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners
The Glucuronidation of {Delta}4-3-Keto C19- and C21-Hydroxysteroids by Human Liver Microsomal and Recombinant UDP-glucuronosyltransferases (UGTs): 6{alpha}- and 21-Hydroxyprogesterone Are Selective Substrates for UGT2B7
Drug Metab. Dispos., March 1, 2007; 35(3): 363 - 370.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Salvatorelli, P. Menna, L. Gianni, and G. Minotti
Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 790 - 800.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. J. Zaya, R. N. Hines, and J. C. Stevens
Epirubicin Glucuronidation and UGT2B7 Developmental Expression
Drug Metab. Dispos., December 1, 2006; 34(12): 2097 - 2101.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette
Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid
Drug Metab. Dispos., September 1, 2006; 34(9): 1539 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Salvatorelli, S. Guarnieri, P. Menna, G. Liberi, A. M. Calafiore, M. A. Mariggio, A. Mordente, L. Gianni, and G. Minotti
Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart: RELATIVE IMPORTANCE OF VESICULAR SEQUESTRATION AND IMPAIRED EFFICIENCY OF ELECTRON ADDITION
J. Biol. Chem., April 21, 2006; 281(16): 10990 - 11001.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Yu, J. K. Ritter, R. J. Krieg, B. Rege, T. H. Karnes, and M. A. Sarkar
EFFECT OF CHRONIC RENAL INSUFFICIENCY ON HEPATIC AND RENAL UDP-GLUCURONYLTRANSFERASES IN RATS
Drug Metab. Dispos., April 1, 2006; 34(4): 621 - 627.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Thibaudeau, J. Lepine, J. Tojcic, Y. Duguay, G. Pelletier, M. Plante, J. Brisson, B. Tetu, S. Jacob, L. Perusse, et al.
Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone
Cancer Res., January 1, 2006; 66(1): 125 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Zhang, W. Zhao, V. A. Roongta, J. G. Mitroka, L. J. Klunk, and M. Zhu
AMIDE N-GLUCURONIDATION OF MAXIPOST CATALYZED BY UDP-GLUCURONOSYLTRANSFERASE 2B7 IN HUMANS
Drug Metab. Dispos., May 1, 2004; 32(5): 545 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. H. Court, S. Krishnaswamy, Q. Hao, S. X. Duan, C. J. Patten, L. L. von Moltke, and D. J. Greenblatt
EVALUATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, MORPHINE, AND CODEINE AS PROBE SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 2B7 (UGT2B7) IN HUMAN LIVER MICROSOMES: SPECIFICITY AND INFLUENCE OF THE UGT2B7*2 POLYMORPHISM
Drug Metab. Dispos., September 1, 2003; 31(9): 1125 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
L. V. Iyer, M. N. Ho, W. M. Shinn, W. W. Bradford, M. J. Tanga, S. S. Nath, and C. E. Green
Glucuronidation of 1'-Hydroxyestragole (1'-HE) by Human UDP-Glucuronosyltransferases UGT2B7 and UGT1A9
Toxicol. Sci., May 1, 2003; 73(1): 36 - 43.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Tang, J. H. Hochman, B. Ma, R. Subramanian, and K. P. Vyas
Acyl Glucuronidation and Glucosidation of a New and Selective Endothelin ETA Receptor Antagonist in Human Liver Microsomes
Drug Metab. Dispos., January 1, 2003; 31(1): 37 - 45.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.